Thomas J. Herzog, MD
Advertisement
Articles by Thomas J. Herzog, MD
Advertisement
Latest Updated Articles
Role of Genomic Instability Scores in Treatment SelectionPublished: December 11th 2024 | Updated:
- Optimizing PARP Inhibitor Duration
Published: December 25th 2024 | Updated:
Defining HRD and its Role in Ovarian CancerPublished: July 20th 2023 | Updated:
- Biomarker Testing in Advanced Ovarian Cancer
Published: December 4th 2024 | Updated:
- Commercially Available HRD Tests for Ovarian Cancer
Published: July 27th 2023 | Updated:
- Brief Overview of Frontline Maintenance Therapy for Advanced Ovarian Cancer
Published: December 18th 2024 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5